Bioequivalence and Bioavailability Forum

Main page Policy Latest Posts Abbreviations

Amlodipine/Valsartan [Design Issues]

posted by Bebac user – Egypt, 2023-09-09 08:34 (371 d 14:05 ago) – Posting: # 23713
Views: 2,884

The combination of Amlodipine and valsartan was published as two periods crossover but after checking the variability of Valsartan, it had more than 30%. Therefore, should I in those cases design this study as replicated or un-replicated ?

Complete thread:

Amlodipine/ValsartanBebac user 2023-09-09 06:34 [Design Issues]
- Amlodipine/Valsartan Helmut 2023-09-12 06:48
  - Amlodipine/Valsartan Kumarnaidu2 2023-12-06 09:36
    - Amlodipine/Valsartan dshah 2023-12-06 16:49
      - Amlodipine/Valsartan Kumarnaidu2 2023-12-07 02:42
    - Use all data and avoid the partial replicate design for the FDA Helmut 2023-12-07 09:01

Admin contact
23,225 posts in 4,879 threads, 1,652 registered users;
40 visitors (0 registered, 40 guests [including 8 identified bots]).
Forum time: 22:40 CEST (Europe/Vienna)

We absolutely must leave room for doubt
or there is no progress and no learning.
There is no learning without having to pose a question.
And a question requires doubt.
People search for certainty.
But there is no certainty. Richard Feynman

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC

Ing. Helmut Schütz